Chemotherapy in the Management of Osteosarcoma and Ewing's Sarcoma
Scott M. Schuetze, MD, PhD, Ann Arbor, Michigan cure rate for patients with osteosarcoma or Ewing's sarcoma has dramatically improved from 5% to 20% to 50% to 60%. 1 This improvement was principally caused by the collaboration of pediatric or medical oncologists with orthopedic oncologists.
In the United States, 2500 new patients are diagnosed with sarcomas of bone annually, 2 and approximately 1000 deaths will result. The peak age incidence for osteosarcoma and Ewing's sarcoma is in the second decade of life (typically around the age of 15 years coincident with adolescent growth spurt). Osteosarcoma and Ewing's sarcoma incidence rates are the same for both sexes until 13 years of age, after which males are more commonly affected. Osteosarcoma has no race-predilection, whereas Ewing's sarcoma is 10 times more common in Caucasians than in American or African blacks, or Asians.
All patients with a suspected bone sarcoma should be referred to a tertiary care center with staff specializing in sarcoma diagnosis and management for evaluation, biopsy, and treatment. The importance of appropriate evaluation by an experienced orthopedic oncologist before biopsy is performed cannot be overemphasized. An improperly placed biopsy may jeopardize the option for a limb-sparing surgery or compromise local tumor control. Ideally, the biopsy should be performed by or in consultation with the surgeon who will resect the sarcoma. Treatment outcomes of high-grade bone sarcomas, including patient survival, may be superior when care is delivered by sarcoma specialist centers. 3, 4 Surgical procedures that completely resect bone sarcomas without amputation may be performed in more than 80% of cases by skilled surgeons. Limb-sparing surgical procedures result in equivalent survival but improved functional outcome compared with amputation. tic spread of cancer to bone is common in breast cancer, prostate cancer, and thyroid cancer. The 3 most common bone sarcomas are osteosarcoma, Ewing's family of tumors, and chondrosarcoma. This article focuses on chemotherapy for patients with osteosarcoma or Ewing's sarcoma. The addition of chemotherapy to the treatment of patients with conventional chondrosarcoma has not been shown to improve survival. In the past 40 years, the United States. The age distribution of affected individuals is bimodal with peaks in the early second and sixth decades. Osteosarcoma may arise on the surface of bone (parosteal and periosteal) or within bone (intramedullary) and may be low-or high-grade. Nearly 90% of osteosarcomas are high-grade. Parosteal and periosteal osteosarcomas are lower-grade neoplasms. However, high-grade osteosarcomas infrequently arise on the surface of bone; therefore, tumor grade cannot be assumed on the basis of location. Tumor grade is the most important factor in considering chemotherapy because high-grade osteosarcomas frequently metastasize and result in markedly poorer survival rates than low-grade osteosarcomas when treated with surgery alone.
Malignant fibrous histiocytoma of bone (MFH-B) is a high-grade spindle cell lesion without osteoid or chondroid formation that arises in bone and accounts for approximately 5% of bone tumors. Treatment of MFH-B with surgery and chemotherapy in a similar manner as high-grade osteosarcoma results in a high rate of tumor response and patient survival; therefore, MFH-B should be treated as aggressively as high-grade osteosarcoma. 6 Several other prognostic factors have been evaluated for patients with high-grade osteosarcoma. Elevated levels of serum alkaline phosphatase and lactate dehydrogenase at diagnosis have been associated with reduced disease-free or overall survival. [7] [8] [9] [10] Axial location of the primary tumor has been identified as an independent risk factor for reduced disease-free survival. 7 The extent of tumor necrosis after chemotherapy has correlated with disease-free survival in multivariate analyses. 8, 11, 12 Patients with less than a 10% residual viable tumor after neoadjuvant chemotherapy were more likely to fare better than patients with a poorer tumor response. Currently, prognostic factors in osteosarcoma are important in clinical trial design and analysis but do not directly impact clinical practice recommendations.
Adjuvant Chemotherapy for Osteosarcoma
Adjuvant chemotherapy is an important component of treatment of localized, high-grade osteosarcoma. Early studies of adjuvant chemotherapy after amputation suggested an improvement in disease-free survival or delay in time to distant recurrence of disease compared with amputation alone performed in an historical group of patients. [13] [14] [15] [16] Randomized trials confirmed that chemotherapy compared with no chemotherapy significantly reduced risk for disease recurrence and improved survival in patients with localized osteosarcoma. 17, 18 Rosen et al. 19 at Memorial Hospital in New York developed a series of neoadjuvant chemotherapy protocols to allow time for surgical planning and construction of osseous and joint prostheses, provide early initiation of systemic therapy to treat micrometastatic disease, and evaluate outcomes related to histologic response of tumor to chemotherapy. Meyers et al. 7 reported a 76% probability of disease-free survival at 5 years from diagnosis in patients younger than 22 years treated at Memorial Hospital with the T10 protocol using methotrexate, doxorubicin, cyclophosphamide, dactinomycin, and bleomycin, which compared favorably with the historical less-than-20% survival rate for patients treated with surgery alone. However, a randomized study performed in multiple centers by the European Osteosarcoma Intergroup (EOI) suggested that the more complicated and protracted T10 chemotherapy regimen may not result in better disease-free or overall survival than treatment with 75 mg/m 2 /cycle of doxorubicin and 100 mg/m 2 /cycle of cisplatin given for 6 cycles. 20 The results from the multicenter study were inferior to the Memorial Hospital results, but compliance and delivered chemotherapy dose intensity in patients treated with the T10 regimen in the randomized study were poor. In addition, the EOI study did not alter adjuvant therapy based on tumor histologic response for practical reasons, which may have biased the results.
A randomized study of doxorubicin, methotrexate, and cisplatin versus doxorubicin, methotrexate, cyclophosphamide, dactinomycin, and bleomycin reported equivalent disease-free survival rates of 75% at 30 months, supporting a place for cisplatin in osteosarcoma therapy. 21 A Southwest Oncology Group trial of doxorubicin, ifosfamide, and dacarbazine (MAID regimen) in advanced sarcomas showed a poor 26% response-rate and median survival of 10 months in adults with osteosarcoma. 22 The authors concluded that cisplatin should be included in therapy for osteosarcoma. Other studies have shown that doxorubicin is an important component of chemotherapy for osteosarcoma; metastasis-free survival rates were worse when doxorubicin was omitted. 23 The value of methotrexate for treating osteosarcoma in adults is controversial. The EOI conducted a random- /cycle for 4 cycles to determine whether methotrexate improves outcome. 24 The study randomized 233 patients younger than 40 years with localized disease, with 198 eligible for analysis. Overall survival was the same between the groups and diseasefree survival was better in the group that did not receive methotrexate. More than twice as many patients receiving methotrexate as those not receiving methotrexate did not complete chemotherapy because of toxicity. The group treated with methotrexate received a lower total dose of doxorubicin and cisplatin, which may have influenced the results. A Cooperative Osteosarcoma Study Group trial has suggested that peak serum methotrexate levels more than 1000 mol after infusion of 12 g/m 2 over 4 hours was associated with better disease-free survival in osteosarcoma than lower concentrations, but this finding has not been confirmed by others. [25] [26] [27] Methotrexate, especially at high doses, is generally more difficult to administer to adults than children because of the potential for reduced renal function from comorbid diseases and prior exposure to nephrotoxic agents. The total dose of methotrexate infused per course is usually capped at 20 g, and close attention must be paid to methotrexate serum levels to minimize the risk for life-threatening toxicity. The toxicity rate from high-dose methotrexate in adults is substantial. 28 Ifosfamide and etoposide have significant antitumor activity in relapsed osteosarcoma and as first-line therapy for metastatic disease in children. 29, 30 However, the addition of ifosfamide to a regimen of cisplatin, doxorubicin, and methotrexate for initial treatment of localized disease did not improve the rate for favorable histologic response or 5-year event-free survival in a randomized comparison with cisplatin, doxorubicin, and methotrexate. 31 Analysis of outcome results from 677 children with localized osteosarcoma showed a 64% and 53% probability of event-free survival at 5 years without or with inclusion of ifosfamide, respectively. A Southwest Oncology Group phase II single arm study in 63 adults with localized osteosarcoma treated with doxorubicin, cisplatin, and ifosfamide did not show improvement in survival compared with prior studies using doxorubicin and cisplatin alone. 32 The EOI also failed to show an advantage to adding ifosfamide to doxorubicin and cisplatin in a phase II study. 33 Investigators at the Karolinska Hospital explored the activity of interferon before widespread adoption of multiagent adjuvant chemotherapy for managing localized high-grade osteosarcoma. Eighty-nine patients received interferon-alpha as adjuvant treatment for 18 months to 5 years. With follow-up of more than 10 years from diagnosis, overall survival was 43% at 10 years and is provocative for antitumor activity of interferon-alpha in osteosarcoma. However, a randomized trial of adjuvant chemotherapy with or without interferon-beta failed to show a survival difference between arms. 21 The Children's Oncology Group (COG) is conducting a randomized study of maintenance peg/interferon alpha-2b for 1 year after surgery in patients showing a favorable histologic response to chemotherapy to evaluate whether interferon, in addition to standard chemotherapy, has a role in the treatment of osteosarcoma.
Tailoring Therapy to Tumor Response
Increasing the number of agents used in neoadjuvant chemotherapy of osteosarcoma is associated with higher proportions of patients obtaining a good histologic response of tumor to treatment (often defined as less than 10% residual viable tumor), but has not similarly improved survival. [34] [35] [36] A different approach to improving outcomes is tailoring adjuvant therapy to the tumor response to pre-operatively administered drugs. Rosen et al. 19 described favorable outcomes for patients with poor histologic response to methotrexatecontaining induction therapy after substitution of cisplatin for methotrexate. But, longer follow-up failed to demonstrate an advantage to altering adjuvant treatment for poor responses. 7 Bacci et al. 37 administered 2 cycles of neoadjuvant methotrexate, doxorubicin, and cisplatin to 164 patients with osteosarcoma localized to an extremity. Patients with a good histologic response received adjuvant methotrexate, doxorubicin, and cisplatin, whereas patients with a poor histologic response received ifosfamide and etoposide in addition to the aforementioned drugs. With a reported average follow-up of 54 months, 57% of the patients with poor histologic response were disease-free, which was significantly better than the 32% event-free survival rate in the group's preceding study of methotrexate and cisplatin. The event-free survival rate in patients with a good histologic response was similar between studies at approximately 70%. Although altering chemotherapy in the adjuvant setting for patients with residual viable tumor after neoadjuvant chemotherapy does not seem to reduce the risk for metastasis, this strategy is being evaluated in the current COG randomized trial. Because even patients with poor tumor response to chemotherapy fare better than historical groups treated with surgery alone, adjuvant chemotherapy should generally not be withheld for a perceived lack of treatment effect on the primary tumor.
Therapy for Advanced/Recurrent Osteosarcoma
The combination of ifosfamide and etoposide is active in relapsed or metastatic osteosarcoma, resulting in objective responses in approximately 60% of patients. 29, 30 The projected 2-year progression-free and overall survival rates were 43% and 55%, respectively. Treating of relapsed osteosarcoma with ifosfamide, etoposide, and methotrexate after primary doxorubicin and cisplatin therapy resulted in an objective response rate of 62% and estimated 2-year survival rate of approximately 50%. 38 Including high-dose methotrexate in the treatment of relapsed osteosarcoma does not seem to improve response or survival rates over ifosfamide and etoposide. Treatment with multiagent chemotherapy after complete remission was obtained with surgery for relapsed osteosarcoma has been associated with improved event-free survival. 39 Gemcitabine combined with docetaxel has activity in various histologic subtypes of sarcoma. An objective partial response and stable disease were observed in 2 osteosarcoma patients when the rate of gemcitabine infusion was fixed at 10 mg/m 2 /min. 40 The Sarcoma Alliance through Research and Collaboration (SARC) cooperative group is conducting a phase II trial of gemcitabine and docetaxel in patients with relapsed or refractory bone sarcomas to formally evaluate activity of the regimen in osteosarcoma, Ewing's sarcoma, and chondrosarcoma.
Ecteinascidin-743, a tetrahydroisoquinoline alkaloid, exhibited minimal activity in a phase II single-agent study in patients with recurrent osteosarcoma. 41 Three minor responses were observed among 23 patients who were evaluable for response, but the median duration of response was only 3 months. Ecteinascidin is currently an experimental agent.
AP23573 is a novel inhibitor of the mammalian target of rapamycin (mTOR). Preliminary analysis of results from a phase II trial of AP23573 in patients with advanced sarcoma has suggested activity of this agent in osteosarcoma. 42 Anecdotal response of a patient with metastatic osteosarcoma to treatment with the mTOR inhibitor, sirolimus, has been reported. 43 Patient participation in clinical studies treating advanced or recurrent osteosarcoma should be encouraged to identify new active agents.
Ewing's Family of Tumors
Ewing's sarcoma is an undifferentiated bone tumor that can also arise in the soft tissues (primitive neuroectodermal tumor) and chest wall (Askin tumor), a spectrum of neoplastic diseases known as the Ewing's sarcoma family of tumors. Ewing's sarcoma accounts for 10% to 15% of malignant bone sarcomas. Its cause is unknown, and it is not associated with exposure to radiation or familial cancer syndromes. Ewing's sarcoma usually occurs in the second or third decades of life, but older individuals can be affected, and outcomes in individuals older than 40 years treated aggressively seem to be as good as in younger patients. 44 Ewing's sarcoma is a high-grade neoplasm and most, if not all, Ewing's sarcoma patients have micrometastatic disease at diagnosis. Relapse rates after local therapy alone exceed 90%. The presence of fever; anemia or an elevated serum lactate dehydrogenase at diagnosis; a pelvic primary tumor; and large tumor volume are poor prognostic factors in patients with localized disease. [45] [46] [47] Favorable histologic response of Ewing's sarcoma to neoadjuvant chemotherapy correlates with survival. 45, 46, [48] [49] [50] Mutation in p53 or deletion of p16/p14ARF correlate with poor histologic response to chemotherapy and a lower survival rate.
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Primary Therapy for Ewing's Sarcoma
The first Intergroup Ewing's Sarcoma Study (IESS) showed a clear advantage for the addition of doxorubicin to cyclophosphamide, dactinomycin, and vincristine in patients with Ewing's sarcoma localized in an extremity. 52 The second IESS showed a survival advantage for 1400 mg/m 2 of cyclophosphamide administered every 3 weeks compared with 500 mg/m 2 of cyclophosphamide given weekly. 53 In a randomized trial, incorporating ifosfamide and etoposide with cyclophosphamide, doxorubicin, and vincristine significantly improved 5-year event-free and overall survival rates for patients with localized, but not metastatic, disease and can be considered standard care. 47 Symptomatic cardiomyopathy occurring years after chemotherapy for Ewing's sarcoma has been reported but is rare. 50 Azoospermia is more likely to develop than permanent amenorrhea. 50 Late recurrence of disease more than 5 years after diagnosis is not rare, and patients should be followed up long-term for recurrence and secondary malignancies.
Despite advances in chemotherapy treatment of localized Ewing's sarcoma, outcome remains poor for patients with metastatic disease. Patients with extrapulmonary metastasis have the lowest survival rate. 54, 55 In a multivariate analysis of 114 patients with metastatic Ewing's sarcoma not involving extrapulmonary sites at diagnosis, complete histologic response of the primary tumor to chemotherapy, unilateral lung involvement, and whole-lung radiation were independently associated with improved event-free survival. 54 The probability of 5-year event-free survival rate in patients who underwent whole-lung radiation was approximately 35%. Pulmonary metastectomy does not impact survival. High-dose chemotherapy or total body irradiation supported by autologous stem cell transplantation failed to improve outcomes in patients with metastatic Ewing's sarcoma. 56, 57 The EuroEwing's Intergroup is currently accruing patients for a randomized study of protracted chemotherapy versus consolidation using high-dose busulfan, melphalan, and autologous bone marrow transplantation. The accrual goal is 1200 patients, which may help define the role of high-dose therapy in Ewing's sarcoma.
Chemotherapy for Relapsed/Refractory Ewing's Sarcoma
Ifosfamide combined with etoposide is active in relapsed Ewing's sarcoma not previously treated with the agents. 58 Cyclophosphamide followed by topotecan daily for 5 days is more active than topotecan alone and is a reasonable option. 55, 59 Irinotecan combined with vincristine is being studied in early-phase trials. High-dose therapy may improve survival in specific subsets, such as patients with chemotherapy-sensitive relapsed disease. 60 The survival rate at 5 years from relapse may approach 20% and seems to be better in patients with more than 2 years from initial diagnosis to relapse. As discussed previously, SARC is conducting a phase II study of gemcitabine and docetaxel in patients with bone sarcomas, including Ewing's sarcoma. Prognosis remains very poor for patients with primary resistant or metastatic disease, and participation in phase II studies is encouraged to help identify additional active agents.
Conclusions
Although osteosarcoma and Ewing's sarcoma are uncommon malignancies, they have considerable impact on families because patients are usually teenagers or young adults. Significant advancement in the cure of these diseases was made during the 1970s and 1980s with the incorporation of chemotherapy into the multidisciplinary management of osteosarcoma and Ewing's sarcoma and improvements in supportive care. The prognosis of patients with metastatic disease, especially involvement of extrapulmonary sites, remains very poor, and identification of new agents with antitumor activity is greatly needed. Because of the rarity of these diseases, all patients with osteosarcoma or Ewing's sarcoma should be encouraged to participate in clinical trials.
